Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
When innovation outpaces access: Closing the gap in chronic lymphocytic leukemia care
New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...